Destiny Pharma PLC (LON:DEST) said Brazil's Industrial Property Office has granted it an additional patent over XF-73, a nasal gel being developed to prevent post-surgical infections such as MRSA.
The Brazilian authorities have issued what is known as a notice of allowance pending full approval next month.
It will be the 84th patent from three patent families covering the XF platform.
In the same announcement, Destiny said it expects to share the results of its ongoing phase IIb trial towards the end of March, after which it will concentrate its efforts on a phase III programme.
“There is also a significant commercial opportunity for XF-73 in the hospital setting which we estimate could generate peak annual product sales of US$1 billion in the US alone,” said the company’s chief executive, Neil Clark in the statement.
Destiny’s product has been awarded both qualifying infectious disease product (QIDP) and Fast Track status by the US Food & Drug Administration (FDA).